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• Study population:  
• Village with high proportion of pig-keeping households (HH) and suspected high rate of 
porcine cysticercosis, Busibwabo sub-location, Busia County, Kenya (Figure 1) 
• Sampling: 
• Three-stage door-to-door community based survey (Figure 2) 
• Pigs: Assessment of individual characteristics, lingual exam (Figure 3) 
• Exam not performed on pigs that were pregnant, lactating, or under 3 months of age 
• Humans: 
• Stage 1: 
• Humans: Assessment of household characteristics, individual survey and epilepsy 
screening questionnaire 
• Stage 2: 
• Screen positive for epilepsy: Neurologist evaluation to confirm epilepsy diagnosis 
and blood test for cysticercal antigen (Ag) 
• Screen negative for epilepsy: A random sample of 2% of individuals who were 
negative on epilepsy screening questions had blood test for cysticercal Ag 
• Stage 3:  
• Confirmed Lifetime Epilepsy ≥5 yrs old: Computed Tomography (CT) brain 
• CT done in Children <5yrs if  focal neurological deficit or positive cysticercal Ag 
• 2% sample of  screen negative and positive cysticercal Ag: CT brain 
• Procedures: 
• Epilepsy Screening: 9-question epilepsy screening questionnaire was adapted from a 
widely used instrument and translated into the predominant local languages12 
• Lifetime Epilepsy: ILAE 1993 criteria.13 
• Porcine Cysticercosis: Presence of one or more palpable lingual cysts 
• Human Cysticercosis: Blood was tested for circulating cysticercal antigen using the 
apDia Cysticercosis Antigen ELISA, a commercially available enzyme immunoassay for 
qualitative determination of viable metacestodes (cysticerci) of Taenia spp. Cut-off 
values were calculated according to kit instructions. 
• Human Neurocysticercosis: Contrast-enhanced Computed Tomography (CT) of the brain 
was performed using standard protocols and read by a radiologist blinded to the 
serostatus and presence or absence of epilepsy 
• Analysis: Fishers exact tests were used to compare proportions. 
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• Epilepsy affects 50 million people worldwide, of 
whom 80% live in resource-limited settings where 
there are high treatment gaps1,2 
• Neurocysticercosis (NCC) is the leading cause of 
acquired epilepsy worldwide3,4 
• In Latin American regions with endemic NCC, epilepsy 
prevalence is 2-3x higher than global rates4-6 
• Human cysticercosis is strongly associated with 
keeping free-ranging pigs and lack of latrines7 
• Most studies from African settings derive only from 
clinic-based settings7-11 
Objectives 
• To estimate the prevalence of epilepsy and          NCC-
associated epilepsy in humans in a region with 
suspected high porcine cysticercosis in Western 
Kenya  
• To estimate the prevalence of human and porcine 
cysticercosis  
• Age- and gender- adjusted human epilepsy 
prevalence is 3-7 times higher than global 
estimates of 5-10 per 1000 population5 
• Human cysticercosis prevalence was moderate 
• Surprisingly, there were no cases of NCC-associated 
epilepsy 
• Prevalence of porcine cysticercosis is comparable 
to other areas of East/Southern Africa but lower 
than Latin America 
• Limitations include: 
• apDia Ag ELISA only detects viable cysticerci and is 
more sensitive in extra-parenchymal disease 
• small absolute number of people with epilepsy 
• porcine lingual exam has limited sensitivity 
• Additional research to identify potential protective 
factors explaining the low prevalence of human 
cysticercosis despite high rates in pigs is essential 
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Figure 1. Map of Study Area. 
Prevalence 
per 1000 
population [95% CI] 
Lifetime Epilepsy 
  Crude 26.2  [15.4-41.7] 
  Crude Female 21.7 [9.4-42.3] 
  Crude Male 32.1 [14.8-60.1] 
  Age-Adjusted 30.4 [12.1-48.8] 
  Age-Sex-Adjusted 36.0 [13.1-58.9] 
Cysticercosis 
  Human 
    Epilepsy 0 [0, 195.0]* 
    Without Epilepsy 83.3 [2.1, 384.8] 
  Porcine 84.5 [31.6, 174.9] 
* One sided 97.5% confidence interval 
Table 1. Prevalence of Epilepsy and Cysticercosis. 
Humans 
• Mean 4.5 people per HH [Range:1-20] 
• 57% were female (368/648)  
• 60% were children <18 yrs (392/648)  
• Among adults:  
• 72% had a primary school education or 
less (185/256)  
• 75% were farmers (193/256)  
• 73% always used latrine (474/648)  
• 27% had a worm in their faeces in the last 
one year (158/579)  
• 2% had taken de-worming medication in 
the last month (14/648)  
• Epilepsy 
• 37 people screened positive for epilepsy  
• of whom 16 were confirmed after 
neurology review 
• One additional individual with epilepsy 
was identified by her mother 
• Crude and adjusted epilepsy prevalence 
is presented in Table 1. 
• Cysticercosis prevalence is presented in 
Table 1 
• No neurocysticercosis was identified. 
Pigs 
• 28% of HH kept pigs (41/145)  
• Mean of 1.8 pigs per HH [Range:1-7] 
• Median age was 4 months [IQR: 2-6]  
• 69% of pigs were always tethered in both 
wet and dry seasons (50/72)   
• No associations were observed between 
porcine cysticercosis and: 
• allowing pigs to range freely in wet 
(p=0.66) or dry (p=0.67) seasons 
• presence of a latrine (p=0.32) or all 
closed latrines (p=0.34) in the HH 
• Having an ill pig in the HH in last 12 
mos (p=0.10)  
• We evaluated 145 households, containing 648 humans and 72 pigs between 2/25-6/3/15  
Figure 3. 
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Figure 2. Recruitment and Study Flow. 
+apDia: apDia Cysticercosis Antigen ELISA above cut-off value; CT+NCC: Contrast-enhanced 
Computed Tomography of the Brain consistent with diagnosis of neurocysticercosis; HH: 
Household. 
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